LJPC - La Jolla Pharmaceutical Company
| Previous Close | 9.76 |
| Open | 9.91 |
| Bid | 0.00 x 1000 |
| Ask | 0.00 x 900 |
| Day's Range | 9.50 - 10.38 |
| 52 Week Range | 5.01 - 24.54 |
| Volume | 429,858 |
| Avg. Volume | 1,224,015 |
| Market Cap | 270.204M |
| Beta (3Y Monthly) | 3.03 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -5.92 |
| Earnings Date | Aug 7, 2017 - Aug 11, 2017 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 19.80 |
- American City Business Journals
GWU developed a life-saving drug. It just sold some royalty rights in an 8-figure deal.
The university struck a deal with Barings to sell some of its U.S. rights for a drug used to treat dangerously low blood pressure.
- Simply Wall St.
Does La Jolla Pharmaceutical (NASDAQ:LJPC) Have A Healthy Balance Sheet?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
- Zacks
La Jolla Pharmaceutical (LJPC) Reports Q2 Loss, Lags Revenue Estimates
La Jolla Pharmaceutical (LJPC) delivered earnings and revenue surprises of 0.00% and -1.04%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
La Jolla Pharmaceutical Company Announces Financial Results for the Three and Six Months Ended June 30, 2019 and Highlights Recent Corporate Progress
SAN DIEGO, Aug. 01, 2019 -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to.
- Zacks
Can GW Pharmaceuticals (GWPH) Deliver a Beat in Q2 Earnings?
On GW Pharmaceuticals' (GWPH) second-quarter conference call, investor focus will be on the initial sales uptick of its newly launched anti-epileptic drug Epidiolex.
- Zacks
CannTrust (CTST) to Report Q2 Earnings: What's in Store?
On CannTrust's (CTST) second-quarter earnings call, investor focus will be on the company's efforts to resolve matters regarding the non-compliant report issued by Health Canada.
- GlobeNewswire
La Jolla Pharmaceutical Company Receives Orphan Designation from FDA for LJPC-0118 (Artesunate) for the Treatment of Malaria
La Jolla Pharmaceutical Company (LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced that the US Food and Drug Administration (FDA) has granted an Orphan Drug Designation for the Investigational Drug Product, LJPC-0118 (artesunate), for the treatment of malaria. “The granting of orphan drug status is a significant milestone for the LJPC-0118 program and highlights the significant unmet medical need for the treatment of malaria,” said George Tidmarsh, M.D., Ph.D., La Jolla’s President and Chief Executive Officer.
- Zacks
La Jolla (LJPC) Secures Positive CHMP Opinion for Giapreza
The CHMP recommends La Jolla's (LJPC) marketing application for Giapreza to treat refractory hypotension in adult patients with septic or distributive shock.
- GlobeNewswire
La Jolla Pharmaceutical Company Receives Positive CHMP Opinion for GIAPREZA™ (angiotensin II) for the Treatment of Refractory Hypotension in Adults with Septic or Other Distributive Shock
La Jolla Pharmaceutical Company (LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for La Jolla’s Marketing Authorisation Application (MAA) for GIAPREZA™ (angiotensin II) for the treatment of refractory hypotension in adults with septic or other distributive shock. “With the CHMP’s adoption of a positive opinion for the Marketing Authorisation Application for GIAPREZA, we are one step closer to bringing this new treatment option to the many critically ill patients suffering from septic or other distributive shock in Europe,” said George F. Tidmarsh, M.D., Ph.D., President and Chief Executive Officer of La Jolla.
- Zacks
Implied Volatility Surging for La Jolla Pharmaceutical (LJPC) Stock Options
La Jolla Pharmaceutical (LJPC) needs investors to pay close attention to the stock based on moves in the options market lately.
- Motley Fool
Here's Why La Jolla Pharmaceutical Has More Than Doubled Over the Last 2 Days
A mid-stage clinical trial has investors excited about the biotech's future.
- GlobeNewswire
La Jolla Pharmaceutical Company Announces Positive Results from Pre-Specified Interim Analysis of Phase 2 Study of LJPC-401 in Patients with Hereditary Hemochromatosis
La Jolla Pharmaceutical Company (LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced positive results from the pre-specified interim analysis of its Phase 2 study of LJPC-401 (synthetic human hepcidin) in patients with hereditary hemochromatosis (HH).
- Simply Wall St.
How La Jolla Pharmaceutical Company (NASDAQ:LJPC) Can Impact Your Portfolio Volatility
If you own shares in La Jolla Pharmaceutical Company (NASDAQ:LJPC) then it's worth thinking about how it contributes...
- Zacks
La Jolla Pharmaceutical (LJPC) Reports Q1 Loss, Misses Revenue Estimates
La Jolla Pharmaceutical (LJPC) delivered earnings and revenue surprises of 10.69% and -11.75%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press
La Jolla Pharmaceutical: 1Q Earnings Snapshot
On a per-share basis, the San Diego-based company said it had a loss of $1.17. The results exceeded Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research ...
- GlobeNewswire
La Jolla Pharmaceutical Company Announces Financial Results for the Three Months Ended March 31, 2019 and Highlights Recent Corporate Progress
SAN DIEGO, May 06, 2019 -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to.
- Zacks
La Jolla Pharmaceutical (LJPC) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
La Jolla Pharmaceutical (LJPC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
GuruFocus.comConsider These 3 Falling Knives
Further, these companies have a GuruFocus financial strength rating of at least 5 out of 10, reducing the bankruptcy rate risk, which is not uncommon among falling knives. Warning! GuruFocus has detected 2 Warning Signs with NCSM. The closing price on Friday was 4.1% off the 52-week low of $3.93 and 355% from the 52-week high of $18.6.
- GlobeNewswire
La Jolla Pharmaceutical Company Announces U.S. FDA’s Grant of Breakthrough Therapy Designation for LJPC-0118 for the Treatment of Severe Malaria
La Jolla Pharmaceutical Company (LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for the New Investigational Drug Product, LJPC-0118, for the treatment of severe malaria. The Breakthrough Therapy designation is an FDA program designed to expedite the development and review of drugs that are intended to treat serious or life-threatening conditions.
- GlobeNewswire
La Jolla Pharmaceutical Company Appoints Darryl Wellinghoff as Chief Commercial Officer
La Jolla Pharmaceutical Company (LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced the appointment of Darryl Wellinghoff as Chief Commercial Officer. “We are excited to welcome Darryl to La Jolla’s leadership team,” said George Tidmarsh, M.D., Ph.D., La Jolla’s President and Chief Executive Officer. “Darryl brings extensive and highly relevant experience and depth of knowledge in sales, marketing, product launch and market access gained as a result of many successful product launches.
- Thomson Reuters StreetEvents
Edited Transcript of LJPC earnings conference call or presentation 4-Mar-19 9:30pm GMT
Q4 2018 La Jolla Pharmaceutical Co Earnings Call
- GlobeNewswire
La Jolla Pharmaceutical Company to Present at the 39th Annual Cowen Healthcare Conference
SAN DIEGO, March 07, 2019 -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to.
- Simply Wall St.
Does La Jolla Pharmaceutical Company’s (NASDAQ:LJPC) CEO Pay Reflect Performance?
In 2012 George Tidmarsh was appointed CEO of La Jolla Pharmaceutical Company (NASDAQ:LJPC). This report will, first, examine the CEO compensation levels in comparison to CEO compensation at companies ofRead More...
- Zacks
Do Options Traders Know Something About La Jolla Pharmaceutical (LJPC) Stock We Don't?
Investors need to pay close attention to La Jolla Pharmaceutical (LJPC) stock based on the movements in the options market lately.
- Benzinga
The Daily Biotech Pulse: Novartis Psoriasis Drug Found Superior, Ascendis Offering, Adamas Earnings
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on March 4) Abbott Laboratories (NYSE: ABT ) Ascendis Pharma A/S ...
